COMMUNIQUÉS West-GlobeNewswire
-
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
31/03/2026 -
Plus Therapeutics Announces Reverse Stock Split
31/03/2026 -
American Shared Hospital Services Reports Fourth Quarter and Full Year 2025 Financial Results
31/03/2026 -
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
31/03/2026 -
KDIGO publishes 2026 Clinical Practice Guideline Draft for Acute Kidney Injury and Acute Kidney Disease
31/03/2026 -
BrightSpring Health Services Completes Sale of ResCare Community Living to Sevita
31/03/2026 -
Weight Watchers Announces Best in Market Self-Pay Wegovy® Pricing for Med+ Members and the Launch of Preferred Subscription Pricing for Wegovy via NovoCare®
31/03/2026 -
Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service
31/03/2026 -
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026
31/03/2026 -
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
31/03/2026 -
LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
31/03/2026 -
60 Degrees Pharmaceuticals Announces 2025 Annual Results
31/03/2026 -
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
31/03/2026 -
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
31/03/2026 -
Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre|CISION® exatecan peptide drug conjugate
31/03/2026 -
Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in global demand for protein
31/03/2026 -
Standing Ovation lève $34,2 M pour la commercialisation à grande échelle de sa technologie de rupture visant à produire des protéines laitières par fermentation, une réponse souveraine et durable à l’explosion de la demande en protéines
31/03/2026 -
SAFE - Forte dynamique de développement au Venezuela
31/03/2026 -
Transactions in connection with share buy-back program
31/03/2026
Pages